Phase II Study of Erdafitinib in Tumors with FGFR Mutations or Fusions

Medicine, Basic Medical Sciences, Oncology,
Erdafitinib   FGFR mutations   Tumor fusions   Phase II study   Oncology  

Study on the Efficacy of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions This academic report is based on the scientific paper “Phase II Study of Erdafitinib in Patients with Tumors with Fibroblast Growth Factor Receptor Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2,” and introduces the...

Phase II Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Phase II Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Medicine, Oncology, Life Sciences, Biochemistry,
FGFR amplification   Erdafitinib   antitumor efficacy   NCI-MATCH trial   Phase II study  

Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...